C
Charlotte Miault
Researcher at Novartis
Publications - 4
Citations - 576
Charlotte Miault is an academic researcher from Novartis. The author has contributed to research in topics: Immune receptor & Binding site. The author has an hindex of 4, co-authored 4 publications receiving 478 citations.
Papers
More filters
Journal ArticleDOI
Oxysterols direct immune cell migration via EBI2
Sébastien Hannedouche,Juan Zhang,Tangsheng Yi,Weijun Shen,Weijun Shen,Deborah Nguyen,João Pereira,Danilo Guerini,Birgit Baumgarten,Silvio Roggo,Ben Wen,Richard Knochenmuss,Sophie Noël,François Gessier,Lisa M. Kelly,Miroslava Vanek,Stephane Laurent,Inga Preuss,Charlotte Miault,Isabelle Christen,Ratnaningrum Karuna,Wei Li,Dong-In Koo,Thomas Suply,Christian Schmedt,Eric C. Peters,Rocco Falchetto,Andreas Katopodis,Carsten Spanka,Marie-Odile Roy,Michel Detheux,Yu Chen,Peter G. Schultz,Charles Y. Cho,Klaus Seuwen,Jason G. Cyster,Andreas W. Sailer +36 more
TL;DR: The identification of 7α,25-dihydroxycholesterol as a potent and selective agonist of EBI2 and its role in the adaptive immune response is described.
Journal ArticleDOI
The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease
Esther K. Schmitt,Meliana Riwanto,Vasan K. Sambandamurthy,Vasan K. Sambandamurthy,Silvio Roggo,Charlotte Miault,Christian Zwingelstein,Philipp Krastel,Christian G. Noble,David Beer,Srinivasa P. S. Rao,Melvin Au,Pornwaratt Niyomrattanakit,Vivian Lim,Jun Zheng,Douglas Jeffery,Kevin Pethe,Luis R. Camacho +17 more
Journal ArticleDOI
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Jiping Fu,Meiliana Tjandra,Christopher Becker,Dallas Bednarczyk,Michael Paul Capparelli,Robert Elling,Imad Hanna,Roger Aki Fujimoto,Markus Furegati,Subramanian Karur,Theresa Kasprzyk,Mark Knapp,Kwan Leung,Xiaolin Li,Peichao Lu,Wosenu Mergo,Charlotte Miault,Simon Ng,David Thomas Parker,Yunshan Peng,Silvio Roggo,Alexey Rivkin,Robert Lowell Simmons,Michael Wang,Brigitte Wiedmann,Andrew H. Weiss,Linda Xiao,Lili Xie,Wenjian Xu,Aregahegn Yifru,Shengtian Yang,Bo Zhou,Zachary Kevin Sweeney +32 more
TL;DR: In this article, the side chain hydrophobicity of the P4 residue of cyclophilin D has been reduced to preserve binding and antiviral potency while decreasing transporter inhibition.
Journal ArticleDOI
FR171456 is a specific inhibitor of mammalian NSDHL and yeast Erg26p
Stephen B. Helliwell,Shantanu Karkare,Marc Bergdoll,Alain Rahier,Juliet R. Leighton-Davis,Celine Fioretto,Thomas Aust,Ireos Filipuzzi,Mathias Frederiksen,John S. Gounarides,Dominic Hoepfner,Andreas Hofmann,Pierre-Eloi Imbert,Rolf Jeker,Richard Knochenmuss,Philipp Krastel,Anais Margerit,Klaus Memmert,Charlotte Miault,N. Rao Movva,Alban Muller,Hans-Ulrich Naegeli,Lukas Oberer,Vivian Prindle,Ralph Riedl,Sven Schuierer,Jessica A. Sexton,Jianshi Tao,Trixie Wagner,Hong Yin,Juan Zhang,Silvio Roggo,Stefan Reinker,Christian N. Parker +33 more
TL;DR: It is shown that FR171456 specifically targets the sterol-4-alpha-carboxylate-3-dehydrogenase (Saccharomyces cerevisiae—Erg26p, Homo sapiens—NSDHL (NAD(P) dependent steroid dehydrogenase-like)), an essential enzyme in the ergosterol/cholesterol biosynthesis pathway, and has broad antifungal activity, suggesting potential additional utility as an anti-infective.